CN103848891B - The antigenic peptide of CCND1 autoantibody identification - Google Patents
The antigenic peptide of CCND1 autoantibody identification Download PDFInfo
- Publication number
- CN103848891B CN103848891B CN201210507571.5A CN201210507571A CN103848891B CN 103848891 B CN103848891 B CN 103848891B CN 201210507571 A CN201210507571 A CN 201210507571A CN 103848891 B CN103848891 B CN 103848891B
- Authority
- CN
- China
- Prior art keywords
- ccnd1
- autoantibody
- lung cancer
- polypeptide
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 119
- 108010058546 Cyclin D1 Proteins 0.000 title claims abstract description 95
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 28
- 102000006311 Cyclin D1 Human genes 0.000 title claims abstract 12
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 78
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 76
- 201000005202 lung cancer Diseases 0.000 claims abstract description 76
- 210000002966 serum Anatomy 0.000 claims abstract description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 239000000523 sample Substances 0.000 claims description 72
- 238000012360 testing method Methods 0.000 claims description 38
- 238000001514 detection method Methods 0.000 claims description 24
- 239000013642 negative control Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000005477 standard model Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 5
- 101100120176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FKS1 gene Proteins 0.000 claims description 2
- 101100006923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cnd1 gene Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 87
- 229920001184 polypeptide Polymers 0.000 abstract description 86
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 83
- 206010028980 Neoplasm Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 230000000391 smoking effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the antigenic peptide of CCND1 autoantibody identification.Wherein, this polypeptide to have as shown in SEQID NO:1-2 aminoacid sequence one of at least.Utilize the antigenic peptide of CCND1 autoantibody of the present invention identification, effectively can detect sample, such as, CCND1 autoantibody in the blood sample (such as serum sample) of lung cancer or doubtful patients with lung cancer.
Description
Technical field
The present invention relates to biomedical sector.Particularly, the present invention relates to antigenic peptide of CCND1 autoantibody identification and uses thereof.More specifically, the present invention relates to the antigenic peptide of a kind of CCND1 autoantibody identification, this polypeptide detect CCND1 antibody in tumour serum purposes, a kind of test kit for detecting CCND1 antibody in sample in preparation.
Background technology
Lung cancer is a kind of malignant disease of serious harm human health, and biological characteristics is very complicated, and early stage Noninvasive diagnosis difficulty, finds the study hotspot that tumor related marker thing has become lung cancer early diagnosis and immunotherapy at present.But it is still few that present stage is applied to clinical tumor markers, and still lack enough susceptibility, specificity and repeatability to the early discovery of lung cancer, therefore, at present in the urgent need to finding effective tumor related marker thing for lung cancer early diagnosis.And research in recent years shows, tumour patient self immune system can produce autoantibody to tumor associated antigen, these autoantibodies are present in the circulation of patients with lung cancer body, even just can occur before lung cancer clinical symptom occurs 5 years, therefore autoantibody may become the tumorigenic early sign thing of monitoring.The advantages such as compared to serum tumor antigenic type mark, it is high that the corresponding autoantibody of serum tumor antigen has abundance simultaneously, easy detection, may become more reliable blood serum tumor markers, will contribute to the early diagnosis of tumour.Therefore, find LuCA corresponding autoantibody, for lung cancer early diagnosis and prognosis Clinical significance of detecting great.But current relevant report is little.
Summary of the invention
The present invention completes based on the following discovery of contriver:
CCND1(Cyclin D1 cyclin D1), belong to the albumen that cell cycle dependant is expressed, form mixture in G1 and G1/S phase and CDK4 and CDK6, cause RB1 phosphorylation further, in cell proliferation, there is vital role.In recent years, there are some researches show that CCND1 is that ovarian cancer occurs namely to change in early days, and in the research of squamous carcinoma of larynx, find that the rising of CCND1 activates relevant to JAK2/STAT3 signal path, point out it to have early stage indicative effect as tumor-marker albumen.Further, contriver finds, detect the change that CCND1 autoantibody earlier can find this significant albumen, namely CCND1 autoantibody may become more efficiently tumor markers.But not yet there is commercial CCND1 autoantibody detection kit.
The present invention is intended to solve the above-mentioned defect of prior art one of at least, and provides a kind of useful business to select.
For this reason, the present invention proposes the antigenic peptide of a kind of CCND1 autoantibody identification.According to embodiments of the invention, its polypeptide active fragment be following one of at least:
1) sequence: HAQTFVALCATDVKFISNPP shown in SEQ ID No:1;
2) sequence: TDVKFISNPPSMVAAGSVVA shown in SEQ ID No:2;
3) aminoacid sequence shown in SEQ ID No:1-2 is through the replacement of amino-acid residue, disappearance or interpolation and the amino acid derived sequence formed.
According to embodiments of the invention, preferably, the antigenic peptide of CCND1 autoantibody of the present invention identification has as HAQTFVALCATDVKFISNPP(SEQ ID NO:1) shown in aminoacid sequence.Thus, the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
In addition, the invention allows for the purposes of antigenic peptide in preparation detection tumour serum CCND1 antibody kit of foregoing CCND1 autoantibody identification.Especially, the tumour that this test kit may be used for detecting is lung cancer.
For this reason, the present invention proposes a kind of test kit for detecting CCND1 antibody in sample.According to embodiments of the invention, this test kit comprises: the antigenic peptide of foregoing CCND1 autoantibody identification.Particularly, according to embodiments of the invention, this test kit can comprise: 96 orifice plates, wraps by the antigenic peptide of foregoing CCND1 autoantibody identification in the hole of described 96 orifice plates.Further, this test kit may further include: negative control sample, described negative control sample is CCND1 antibody is negative serum, or/may further include extraly: standard model, described standard model is that CCND1 antibody concentration is respectively 1U/ml, the serum of 5U/ml, 10U/ml, 15U/ml.According to embodiments of the invention, the concentration of the antigenic peptide of CCND1 autoantibody identification can be, each reacting hole 1 μ g/ml.According to embodiments of the invention, especially, the tumour that this test kit may be used for detecting is lung cancer.
For this reason, in still another aspect of the invention, the present invention proposes a kind of isolated polypeptide.According to embodiments of the invention, this polypeptide to have as shown in SEQ ID NO:1-2 aminoacid sequence one of at least.That is, polypeptide has as one of following shown aminoacid sequence:
HAQTFVALCATDVKFISNPP（SEQ ID NO:1）；
TDVKFISNPPSMVAAGSVVA（SEQ ID NO:2）。
According to embodiments of the invention, utilize the polypeptide with above-mentioned aminoacid sequence, effectively can detect sample, such as, CCND1 autoantibody in the blood sample (such as serum sample) of lung cancer or doubtful patients with lung cancer.
According to embodiments of the invention, preferably described polypeptide has as HAQTFVALCATDVKFISNPP(SEQ ID NO:1) shown in aminoacid sequence.Thus, the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
In still another aspect of the invention, the present invention proposes polypeptide noted earlier in the purposes detecting CCND1 autoantibody in sample.
According to embodiments of the invention, described sample is the blood sample from lung cancer or doubtful patients with lung cancer and healthy volunteer.
In still another aspect of the invention, the present invention proposes polypeptide noted earlier and preparing the purposes in test kit, described test kit is for detecting the CCND1 autoantibody in sample.
According to embodiments of the invention, described sample is the blood sample from lung cancer or doubtful patients with lung cancer and healthy volunteer.
In still another aspect of the invention, the present invention proposes a kind of test kit for detecting CCND1 autoantibody in sample.According to embodiments of the invention, this test kit comprises: foregoing polypeptide.Thus, utilize according to embodiments of the invention, can effectively detect the CCND1 autoantibody in sample by polypeptide according to the present invention.
According to embodiments of the invention, this test kit may further include: be suitable for the reagent carrying out ELISA detection.Thus, ELISA detection method can be passed through, utilize polypeptide according to the present invention to detect the CCND1 autoantibody in sample, thus the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
According to embodiments of the invention, described polypeptide is arranged in 96 orifice plates.Thus, can detect easily high-throughput.The efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
According to embodiments of the invention, described sample is the blood sample from lung cancer or doubtful patients with lung cancer and healthy volunteer.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Embodiment
Be described below in detail embodiments of the invention, described embodiment is intended to for explaining the present invention, and can not be interpreted as limitation of the present invention.
The antigenic peptide of CCND1 autoantibody identification
According to an aspect of the present invention, the present invention proposes the antigenic peptide of a kind of CCND1 autoantibody identification.According to embodiments of the invention, its polypeptide active fragment be following one of at least:
1) sequence: HAQTFVALCATDVKFISNPP shown in SEQ ID No:1;
2) sequence: TDVKFISNPPSMVAAGSVVA shown in SEQ ID No:2;
3) aminoacid sequence shown in SEQ ID No:1-2 is through the replacement of amino-acid residue, disappearance or interpolation and the amino acid derived sequence formed.
According to embodiments of the invention, preferably, the antigenic peptide of CCND1 autoantibody of the present invention identification has as HAQTFVALCATDVKFISNPP(SEQ ID NO:1) shown in aminoacid sequence.Thus, the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
In another aspect of the invention, the present invention proposes a kind of isolated polypeptide.According to embodiments of the invention, this polypeptide to have as shown in SEQ ID NO:1-2 aminoacid sequence one of at least.That is, polypeptide has as one of following shown aminoacid sequence:
Sequence: HAQTFVALCATDVKFISNPP shown in SEQ ID No:1;
Sequence: TDVKFISNPPSMVAAGSVVA shown in SEQ ID No:2.
It should be noted that, aforementioned polypeptides all comes from (full length sequence of CCND1 is shown in NCBI NP_444284.1) corresponding to the full length sequence of CCND1.In addition, term " polypeptide " used in this article refers to that at least two amino acid are connected by peptide bond and the oligomer obtained, and wherein, the number of the amino-acid residue comprised in polypeptide is also not particularly limited.According to embodiments of the invention, polypeptide can contain 20 amino acid.Certainly, it will be appreciated by persons skilled in the art that and can also carry out chemically modified to aforementioned polypeptides, to increase the antigenicity of polypeptide, contribute to polypeptide bag by the bottom of elisa plate.According to embodiments of the invention, utilize the polypeptide with above-mentioned aminoacid sequence, effectively can detect sample, such as, CCND1 autoantibody in the blood sample (such as serum sample) of lung cancer or doubtful patients with lung cancer.Contriver finds that the aforementioned polypeptides obtained from CCND1 complete sequence can as the epitope of CCND1, can with the reaction of CCND1 autoantibody specificity in blood sample, thus, can effectively for the CCND1 autoantibody in detected object blood sample, thus, can effectively for examination lung cancer suspected patient serum, the diagnosis for lung cancer provides a new test rating.
According to embodiments of the invention, preferably described polypeptide has as HAQTFVALCATDVKFISNPP(SEQ ID NO:1) shown in aminoacid sequence.Thus, the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.
It will be appreciated by persons skilled in the art that can effectively by conventional synthesis process, synthesis aforementioned polypeptides, thus replaces recombinant expressed biosynthesizing mode.
The application of the antigenic peptide of CCND1 autoantibody identification and test kit
Thus, in still another aspect of the invention, the invention allows for polypeptide noted earlier in the purposes detecting CCND1 autoantibody in sample.According to embodiments of the invention, can the type of the sample detected be carried out by aforementioned polypeptides and be not particularly limited.According to embodiments of the invention, preferred sample is the blood sample from lung cancer or doubtful patients with lung cancer.Thus, the CCND1 autoantibody in the blood sample of polypeptide detection of lung cancer or doubtful patients with lung cancer can be utilized, can determine whether patient suffers from malignant tumour thus, provide supplementary means for malignant tumour detects, or the early screening of malignant tumour such as lung cancer is provided.In addition, by the existence of CCND1 autoantibody in detected object blood, and prognosis prediction analysis can also be carried out to patient.
Polypeptide of the present invention is utilized to detect the method for CCND1 autoantibody in sample and be not particularly limited.According to embodiments of the invention, can enzyme linked immunosorbent assay (ELISA) method be passed through, detect the CCND1 autoantibody in sample by polypeptide of the present invention.Thus, the efficiency of the CCND1 autoantibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.Exemplarily, following method can be adopted to utilize CCND1 antibody in the blood sample of polypeptide detection of lung cancer or doubtful patients with lung cancer:
First, with the carbonate buffer solution (NaCO of pH9.6
30.159g, NaHCO
30.293g, adds water to 100ml, and pH value is 9.6) dilution polypeptide to 1 μ g/ml, join in the hole of 96 hole enzyme plates with the amount in 100 μ l/ holes, after shrouding film phonograph seal, 4 DEG C are spent the night.
Next, discard the liquid in hole, 0.1%TBS-T lavation buffer solution (its compound method is: NaCl8.7g, Tris 1.21g, adds deionized water to 1000ml, pH 7.5, then adds Tween-201ml) detersive enzyme target 5 times, each 3min.
Then, (its compound method is Xiang Kongzhong interpolation 5%BSA/0.05%TBS-T Block buffer: NaCl0.87g, Tris 0.121g, add deionized water to 100ml, pH 7.5, then add Tween-20 0.5ml, BSA 5g), every hole 300 μ l, hatches 1h for 37 DEG C after shrouding film phonograph seal.
Then, testing sample is added.With 5%BSA/0.05%TBS-T Block buffer dilute serum, Dilution ratio is 1:100, discard liquid in hole completely, every hole increase serum diluent 100 μ l, the multiple hole of every routine serum sample 3,2 Positive control wells set up by every plate, add known positive serum, 2 blank control wells set up by every plate, add 0.1%TBS-T lavation buffer solution.2h is hatched for 37 DEG C after shrouding film phonograph seal.Discard liquid in hole, detersive enzyme target 5 times, each 3min.
Then, second antibody immune response is carried out.Utilize 5%BSA/0.05%TBS-T Block buffer to dilute the Goat anti human IgG of horseradish peroxidase-labeled, Dilution ratio 1:5000, every hole adds 100 μ l, hatches 1h for 37 DEG C after shrouding film phonograph seal.Discard liquid in hole, detersive enzyme target 5 times, each 3min.
Then, substrate colour developing is added.Conveniently ELISA kit specification sheets (such as health is century TMB colouring reagents box), add chromogenic substrate, every hole adds 100 μ l, and develop the color under room temperature lucifuge condition 10min, and every hole adds 50 μ l 2M H
2sO
4termination reaction.
Then, optical density(OD) OD value is measured under microplate reader 492nm wavelength condition.
Finally, based on the difference of obtained optical density(OD) OD value and predetermined reference value, determine whether testing sample comes from and suffer from patients with lung cancer.According to embodiments of the invention, the blood sample making a definite diagnosis cancer patients and Healthy People (healthy volunteer) can be utilized to carry out numerical value that parallel test obtains is as predetermined reference value.
Such as, the autoantibody of the anti-CCND1 in blood sample is detected by ELISA method.If the optical density value of the chromogenic enzyme substrate reaction in sample to be tested is higher than X+2SD, then test serum is lung cancer suspected patient serum, wherein, in X+2SD, X is the OD average of the chromogenic enzyme substrate reaction in Healthy Human Serum, and 2SD is two times of standard deviations of the optical density value that the chromogenic enzyme substrate in Healthy Human Serum reacts.Particularly, according to embodiments of the invention, X+2SD value of the present invention is obtained by following method: according to the aforementioned method utilizing polypeptide of the present invention to detect CCND1 autoantibody in sample, adopt 89 routine normal healthy controls blood samples, measure the OD value of its chromogenic enzyme substrate reaction, after the OD value recorded is met normal distribution (p>0.05) with single sample K-S check analysis, calculate and obtain the mean value (X=0.18) of each OD value and standard deviation (SD=0.08), then with X+2SD(0.34) be the upper limit of normal value.
According to a further aspect in the invention, the invention allows for the purposes of antigenic peptide in preparation detection tumour serum CCND1 antibody kit of foregoing CCND1 autoantibody identification.Especially, the tumour that this test kit may be used for detecting is lung cancer.In addition, this test kit is utilized by the existence of CCND1 autoantibody in detected object blood, and prognosis can also to be carried out to the such as radiotherapeutic reaction of patient for treatment's method.
For this reason, in accordance with a further aspect of the present invention, the present invention proposes a kind of test kit for detecting CCND1 antibody in sample.According to embodiments of the invention, this test kit comprises: the antigenic peptide of foregoing CCND1 autoantibody identification.Particularly, according to embodiments of the invention, this test kit can comprise: 96 orifice plates, wraps by the antigenic peptide of foregoing CCND1 autoantibody identification in the hole of described 96 orifice plates.Further, this test kit may further include: negative control sample, described negative control sample is CCND1 antibody is negative serum, or/may further include extraly: standard model, described standard model is that CCND1 antibody concentration is respectively 1U/ml, the serum of 5U/ml, 10U/ml, 15U/ml.According to embodiments of the invention, the concentration of the antigenic peptide of CCND1 autoantibody identification can be, each reacting hole 1 μ g/ml.According to embodiments of the invention, especially, the tumour that this test kit may be used for detecting is lung cancer.In another aspect of the invention, the present invention proposes polypeptide noted earlier and preparing the purposes in test kit, described test kit is for detecting the CCND1 autoantibody in sample.According to embodiments of the invention, described sample is the blood sample from lung cancer or doubtful patients with lung cancer.Thus, the CCND1 autoantibody in the blood sample of polypeptide detection of lung cancer or doubtful patients with lung cancer can be utilized, can determine whether patient suffers from malignant tumour thus, provide supplementary means for malignant tumour detects, or the progress of monitoring malignant tumour such as lung cancer.
In still another aspect of the invention, the present invention proposes a kind of test kit for detecting CCND1 autoantibody in sample.According to embodiments of the invention, this test kit comprises: foregoing polypeptide.Thus, utilize according to embodiments of the invention, can effectively detect the CCND1 antibody in sample by polypeptide according to the present invention.According to embodiments of the invention, this test kit may further include: be suitable for the reagent carrying out ELISA detection.Thus, can ELISA detection method be passed through, utilize polypeptide according to the present invention to detect the CCND1 antibody in sample, thus the efficiency of the CCND1 antibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.According to embodiments of the invention, described polypeptide is arranged in 96 orifice plates, such as, can wrap by the hole of 96 orifice plates, such as can by conventional processing as undertaken by coating buffer and retardance liquid.Thus, can detect easily high-throughput.The efficiency of the CCND1 antibody in the blood sample utilizing polypeptide detection of lung cancer or doubtful patients with lung cancer can be improved further.Can also comprise other reagent in test kit, such as dcq buffer liquid, sample dilution buffer, tmb substrate solution, reaction terminating liquid, two of horseradish enzyme labelling resists, negative control sample, standard model.Wherein, negative control sample is CCND1 antibody is negative serum, and standard model is that CCND1 antibody concentration is respectively 1U/ml, the serum of 5U/ml, 10U/ml, 15U/ml.
According to embodiments of the invention, described sample is the blood sample from lung cancer or doubtful patients with lung cancer.
In addition, this test kit is utilized by the existence of CCND1 autoantibody in detected object blood, and prognosis can also to be carried out to the such as radiotherapeutic reaction of patient for treatment's method.
It should be noted that, in this article, sometimes also by " antigenic peptide of CCND1 autoantibody identification " referred to as " polypeptide ", by " CCND1 autoantibody " referred to as " CCND1 antibody ".
Below by specific embodiment, the present invention is made an explanation.It should be noted that, the following example is only illustrative, and does not limit the present invention in any way.In addition, all appts adopted in the following example, material etc. are commercially available, as the operation do not explicitly not pointed out in the examples below that, can be undertaken by the working method of those skilled in the art's routine.
The preparation of embodiment 1 polypeptide
1.1 general method
According to the full length amino acid residue sequence (NP_444284.1) of CCND1 albumen, adopt situ synthesis techniques to be the polypeptide chip (Piptide Array) of the polypeptide of 20 at activated cellulose film surface composition length, each polypeptide is overlapping 10 amino-acid residues of order directly.
1.2 fabricated in situ prepare polypeptide chip (Piptide Array)
Peptide synthesizer ASP SL(Germany is carried out according to albumen and polypeptide amino acid residues in length, overlap length, intavis company) setting of MutilPep synthesis sequence of control, add the nitrocellulose filter surface synthesis site of a kind of specific amino acids to activation according to time variable control at each synthesis cycle, and between catalytic amino acid, peptide bond is formed.Synthetic peptide chain length is 20 amino-acid residues, need carry out the reaction in 20 cycles, according to the operating process of ASP SL Peptide synthesizer, the native amino acid solution of 20 kinds of FMOC-radical protections is put into position corresponding on machine.Between each cycle, amino acid will through capping, and a series of processes such as FMOC-group deprotection could be combined with next amino acid, during last end cycle, amino acid whose side chain protected group be taken off.The steps include: that the amino acid of specifying is added drop-wise to specific position on nitrocellulose filter by Peptide synthesizer ASP SL, the solution of acetic anhydride of 2% washes film 5 minutes, and dimethyl formamide washes film 5 times, each 2 minutes.The piperidine solution of 20% is washed film and is sloughed FMOC-blocking group in 10 minutes, and dimethyl formamide washes film 5 times, each 2 minutes.Ethanol washes film 2 times, each 2 minutes, dries.Repeat aforesaid operations, until complete 20 cycles, during last end cycle, the piperidine solution of 20% washes film 2 times, each 10 minutes.Dimethyl formamide washes film 5 times, each 2 minutes.Air dried overnight after film 2 times washed by ethanol.Finally, 10ml trifluoroacetic acid, 300 μ l methylene dichloride, 200 μ l water fully mix, and wash film 1 hour, slough side chain protected group with mixed solution, and methylene dichloride washes film 5 times, each 2 minutes.Dimethyl formamide washes film 5 times, each 2 minutes.Ethanol dries after washing film 2 times.Save backup-20 DEG C of sealings after polypeptide chip synthesis.
Embodiment 2 screens the polypeptide relevant to lung cancer
The aquation of 2.1 polypeptide chips
First, the polypeptide chip prepared by embodiment 1 is immersed in 40ml 100% ethanol, shaking table shakes 5 minutes.Then, this polypeptide chip is immersed in 40ml 75% ethanol, shaking table shakes 5 minutes.Next, polypeptide chip is immersed in 40ml 50% ethanol, shaking table shakes 5 minutes.Then, add 150ml PBS to soak 30 minutes (fade completely with the white point on film and be as the criterion).Finally, just polypeptide chip immerses in 40ml 5% skim-milk/PBS-T solution, and incubated at room temperature is closed for 3 hours.
2.2 polypeptide array and sero-reaction
By 10 routine Serum of Patients with Lung Cancer balanced mix, prepare Sera of Lung Cancer pond, be prepared into immune response liquid with 5% skim-milk/PBS-T solution 1: 1000 dilution, polypeptide chip put into hybridization bag, by 0.1ml/cm
2add reaction solution, remove all bubbles in bag, film sealing machine seals, 4 DEG C of shaken overnight gently.
By 10 routine normal healthy controls serum mixing, preparation normal healthy controls serum pond, is prepared into immune response liquid with 5% skim-milk/PBS-T solution 1:1000 dilution, polypeptide chip is put into hybridization bag, by 0.1ml/cm
2add reaction solution, remove all bubbles in bag, film sealing machine seals, 4 DEG C of shaken overnight gently.
After seroimmunity reaction terminates, cut off hybridization bag, discard reaction solution, PBS-T 40ml washes polypeptide chip 6 times, each 10 minutes, polypeptide chip is put into hybridization bag, adds the Goat anti human IgG solution of 1:10000 dilution, by 0.1ml/cm
2add two anti-reaction solutions, seal hybridization bag, room temperature with gentle vibrates 2 hours, and 40ml PBS-T washes film 3 times, each 10 minutes, and 40ml PBS washes film 3 times, each 10 minutes.
Next, carry out ECL development, exposure, scans film, with AlphaView software system analysis image.
2.3 screening
According to above-mentioned Piptide Array immune response result, select with Serum of Patients with Lung Cancer reacting positive and differential peptides point (sequence in table 1) seronegative with normal healthy controls group, composition polypeptide original position Dot-Blot film, according to preparation method described in embodiment 1, preparation comprises these 5 polypeptide and to impinging upon interior polypeptide chip, calculating the positive frequency value of each point by carrying out immune response with 29 routine Serum of Patients with Lung Cancers, determining specific sequence (seeing the following form 1).As shown in table 1, wherein, that susceptibility is the highest is sequence: HAQTFVALCATDVKFISNPP shown in SEQ ID No:1.
Table 1
| Sequence number (SN) | Title | Sequence | Positive rate |
| 1 | SEQ ID No:1 | HAQTFVALCATDVKFISNPP | 3/18(16.7%) |
| 2 | SEQ ID No:2 | TDVKFISNPPSMVAAGSVVA | 0/18(0%) |
Embodiment 3ELISA checks
Polypeptide HAQTFVALCATDVKFISNPP(SEQ ID NO:1 to obtain in embodiment 2) for antigen coated 96 orifice plates, ELISA method is used following sample to be carried out to the detection of CCND1 autoantibody: 407 routine Serum of Patients with Lung Cancers, 66 routine lung benign disease patients serums, 89 routine Healthy People control serums.
Concrete detection method is as follows:
First, with Peptide synthesizer MultiPep RS according to amino-acid residue order improvement on synthesis HAQTFVALCATDVKFISNPP(SEQ ID NO:1 in sequence table), and by obtained peptide coupling KLH, to increase the antigenicity of polypeptide, contribute to polypeptide bag by the bottom of elisa plate.
Bag quilt: with the carbonate buffer solution (NaCO of pH9.6
30.159g, NaHCO
30.293g, adds water to 100ml, and pH value is 9.6) dilute the polypeptide HAQTFVALCATDVKFISNPP(SEQ IDNO:1 synthesized) to 1 μ g/ml, adding 96 hole enzyme plates with 100 μ l/well, after shrouding film phonograph seal, 4 DEG C are spent the night.
Washing: discard the liquid in hole, 0.1%TBS-T lavation buffer solution (its compound method is: NaCl 8.7g, Tris 1.21g, adds deionized water to 1000ml, pH 7.5, then adds Tween-201ml) detersive enzyme target 5 times, each 3min.
Close: (its compound method is 5%BSA/0.05%TBS-T Block buffer: NaCl 0.87g, Tris0.121g, adds deionized water to 100ml, pH 7.5, then add Tween-20 0.5ml, BSA 5g), every hole 300 μ l, hatches 1h for 37 DEG C after shrouding film phonograph seal.
Add serum to be checked: with 5%BSA/0.05%TBS-T Block buffer dilute serum, Dilution ratio is 1:100, discard liquid in hole completely, every hole increase serum diluent 100 μ l, the multiple hole of every routine serum sample 3,2 Positive control wells set up by every plate, add known positive serum, 2 blank control wells set up by every plate, add 0.1%TBS-T lavation buffer solution.2h is hatched for 37 DEG C after shrouding film phonograph seal.Discard liquid in hole, detersive enzyme target 5 times, each 3min.
Second antibody immune response: the Goat anti human IgG of 5%BSA/0.05%TBS-T Block buffer dilution horseradish peroxidase-labeled, Dilution ratio 1:5000, every hole adds 100 μ l, hatches 1h for 37 DEG C after shrouding film phonograph seal.Discard liquid in hole, detersive enzyme target 5 times, each 3min.
Add substrate colour developing: use TMB colouring reagents box, the specification sheets provided according to institute of manufacturers (health is century), develop the color under room temperature lucifuge condition 10min, and every hole adds 50 μ l 2M H
2sO
4termination reaction.
Detect: under microplate reader 492nm wavelength condition, measure optical density(OD) OD value.
Then, the OD value of the above-mentioned 89 routine normal healthy controls groups recorded is met after normal distribution (p>0.05) through single sample K-S check analysis, calculate mean value X and the standard deviation SD of its OD value, represent the upper limit of the autoantibody normal value of anti-CCND1 specific polypeptides in normal healthy controls serum with X+2SD.As a result, the mean value X=0.18 of each OD value, standard deviation SD=0.08, then in normal healthy controls serum, the upper limit X+2SD of the autoantibody normal value of anti-CCND1 specific polypeptides is 0.34.
Then, based on the optical density(OD) OD value of each serum sample of above-mentioned acquisition, and the upper limit X+2SD(0.34 of the autoantibody normal value of anti-CCND1 specific polypeptides in normal healthy controls serum), determine whether each serum sample is polypeptide autoantibodies shown in SEQ ID NO:1, and to utilizing the positive rate of this polypeptide detection of lung cancer and multiple Benign Pulmonary Nodules Disease change of serum C CND1 autoantibody to analyze.
Result is as follows:
| Sample type | Number of cases | Antibody positive rate |
| Lung cancer | 407 | 85/407(20.9%) |
| Benign lesion contrasts | 66 | 3/24(4.5%) |
| Normal healthy controls | 89 | 5/89(5.6%) |
The comparative result of positive and negative number of cases is as follows:
| Autoantibody | Patients with lung cancer number | Non-lung cancer patient number |
| Positive | 85(a, i.e. true positives) | 8(b, i.e. false positive) |
| Negative | 322(c, i.e. false negative) | 146 (d, i.e. true negatives) |
Then, based on upper table, according to specificity, susceptibility and the negative positive predictive value of polypeptide autoantibody shown in following formulae discovery anti-SEQ ID NO:1 in patients with lung cancer diagnosis:
Susceptibility=(a/a+c) × 100%
Specificity=(d/b+d) × 100%
Positive predictive value=(a/a+b) × 100%
Negative predictive value=(d/c+d) × 100%
Result is as shown in the table:
| Autoantibody | Susceptibility | Specificity | Positive predictive value | Negative predictive value |
| CCND1 | 20.9% | 94.8% | 91.4% | 31.2% |
According to detected result, the sensitivity utilizing the polypeptide shown in SEQ ID NO:1 to detect CCND1 autoantibody can reach 20.9%, and specificity reaches 94.8%, and positive prediction rate reaches 91.4%, and negative predictive rate reaches 31.2%.
In addition, by to the comparison of CCND1 autoantibodies rate of Serum of Patients with Lung Cancer with different smoking history, contriver finds: CCND1 autoantibody is different in the positives rate of the patients with lung cancer with different smoking history, patient's positive rate of smoking is higher than the patient of non-smoking, difference has statistical significance, P=0.005, other 10 routine smoking histories are indefinite, exclude statistics.
| Smoking history | Number of cases | Positive rate |
| Smoking | 196 | 56/196(28.6%) |
| Non-smoking | 126 | 19/126(15.1%) |
In sum, contriver finds, the CCND1 own level of patients with lung cancer is higher than lung benign disease patient and normal healthy controls group; The patients with lung cancer positive rate of smoking is higher than the patient of non-smoking.Thus, demonstrate the antigenic peptide of CCND1 autoantibody of the present invention identification, especially the polypeptide shown in SEQ ID NO:1, the auxiliary diagnosis of lung cancer can be effective to, especially the early screening of lung cancer.
In the description of this specification sheets, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (8)
1. an antigenic peptide for CCND1 autoantibody identification, is characterized in that, its aminoacid sequence is as shown in SEQ ID No:1: HAQTFVALCATDVKFISNPP.
2. the purposes of antigenic peptide in preparation detection of lung cancer change of serum C CND1 antibody kit of CCND1 autoantibody according to claim 1 identification.
3. for detecting a test kit for CCND1 antibody in sample, it is characterized in that, comprising:
The antigenic peptide of CCND1 autoantibody according to claim 1 identification.
4. test kit according to claim 3, is characterized in that, comprising:
96 orifice plates, wrap by the antigenic peptide of CCND1 autoantibody according to claim 1 identification in the hole of described 96 orifice plates.
5. test kit according to claim 4, is characterized in that, comprises further: negative control sample, and described negative control sample is CCND1 antibody is negative serum.
6. test kit according to claim 4, is characterized in that, comprises further: standard model, and described standard model is that CCND1 antibody concentration is respectively 1U/ml, the serum of 5U/ml, 10U/ml, 15U/ml.
7. test kit according to claim 4, is characterized in that, the concentration of the antigenic peptide of described CCND1 autoantibody identification is, each reacting hole 1 μ g/ml.
8. test kit according to claim 3, is characterized in that, described sample is Sera of Lung Cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210507571.5A CN103848891B (en) | 2012-11-30 | 2012-11-30 | The antigenic peptide of CCND1 autoantibody identification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210507571.5A CN103848891B (en) | 2012-11-30 | 2012-11-30 | The antigenic peptide of CCND1 autoantibody identification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103848891A CN103848891A (en) | 2014-06-11 |
| CN103848891B true CN103848891B (en) | 2015-09-09 |
Family
ID=50857042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210507571.5A Active CN103848891B (en) | 2012-11-30 | 2012-11-30 | The antigenic peptide of CCND1 autoantibody identification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103848891B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101280014A (en) * | 2008-02-29 | 2008-10-08 | 吉林大学 | Anti-Cyclin D1 human single-chain antibody |
| WO2011151403A1 (en) * | 2010-06-02 | 2011-12-08 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
| CN102321181A (en) * | 2011-09-19 | 2012-01-18 | 郑州大学 | Cyclin D/CDK4 (Cyclin-Dependent Kinase) originated chimeric polypeptide with anti-tumor activity and application as anti-tumor medicament |
| CN102690878A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CDK18 gene and expression product thereof |
| CN102690875A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CDK14 gene and expression product thereof |
-
2012
- 2012-11-30 CN CN201210507571.5A patent/CN103848891B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101280014A (en) * | 2008-02-29 | 2008-10-08 | 吉林大学 | Anti-Cyclin D1 human single-chain antibody |
| WO2011151403A1 (en) * | 2010-06-02 | 2011-12-08 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
| CN102690878A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CDK18 gene and expression product thereof |
| CN102690875A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CDK14 gene and expression product thereof |
| CN102321181A (en) * | 2011-09-19 | 2012-01-18 | 郑州大学 | Cyclin D/CDK4 (Cyclin-Dependent Kinase) originated chimeric polypeptide with anti-tumor activity and application as anti-tumor medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103848891A (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109142755B (en) | Four-autoantibody combined detection kit for diagnosing early esophageal squamous cell carcinoma and application | |
| US10705089B2 (en) | Methods and kits for the diagnosis of cancer | |
| US11307203B2 (en) | Using phage epitopes to profile the immune response | |
| CN108107218A (en) | Antibody determination | |
| CN105527435B (en) | Protein chip, protein-chip diagnostic kit method of preparation and use | |
| CN104345154B (en) | A kind of double-antibody sandwich test kit detecting many tumors relevant " the box-like mark of polypeptide-protein groups " | |
| CN103848889B (en) | The antigenic peptide of IGF2BP1 autoantibody identification | |
| CN104155457B (en) | Relevant " the box-like mark of the polypeptide-protein groups " detection kit of a kind of colorectal cancer | |
| CN107422125A (en) | The urine protein mark related to Myometrial involvement carcinoma of urinary bladder | |
| CN106220722B (en) | The antigen polypeptide and application thereof of DKK1 autoantibody identification | |
| JP5856956B2 (en) | Blood test method | |
| CN103848891B (en) | The antigenic peptide of CCND1 autoantibody identification | |
| WO2013038696A1 (en) | Molecular marker for early indentification of pleural mesothelioma patients, and expression analysis method for same | |
| Johnson et al. | Germ cell tumors express a specific alpha‐fetoprotein variant detectable by isoelectric focusing | |
| CN103848890B (en) | The antigenic peptide of MUC1 autoantibody identification | |
| KR20120116518A (en) | Xage-1a marker for early diagnosis of lung cancer and uses thereof | |
| EP3067697B1 (en) | Method for reducing non-specific reactions in immunoassay of anti-htlv antibodies | |
| CN103848892A (en) | Antigen polypeptide capable of recognizing UROD autoantibody | |
| CA2799359C (en) | Method for the diagnosis/prognosis of colorectal cancer | |
| CN111487411A (en) | Novel application of CEACAM1 polypeptide | |
| CN104316695A (en) | Double-antibody sandwich kit for detecting polypeptide-protein combined type marker related to liver cancer and hepatic cirrhosis | |
| US20120225441A1 (en) | Protein markers for detecting liver cancer and method for identifying the markers thereof | |
| US20130157291A1 (en) | DIAGNOSTIC MARKER FOR LUNG CANCER COMPRISING HPaR AS ACTIVE INGREDIENT | |
| KR102131860B1 (en) | Biomarker Composition for Diagnosing Colorectal Cancer Specifically Binding to Arginine-methylated Gamma-glutamyl Transferase 1 | |
| CN105884872B (en) | The antigen polypeptide and application thereof of LppZ antibody identification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240107 Address after: 101199 Courtyard 9 Beiguan Street, Tongzhou District, Beijing Patentee after: Beijing Chest Hospital, Capital Medical University Patentee after: BEIJING TUBERCULOSIS AND THORACIC TUMOR Research Institute Address before: 101149 No. 97, Ma factory, Beijing, Tongzhou District Patentee before: BEIJING TUBERCULOSIS AND THORACIC TUMOR Research Institute |